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ABSTRACT
Objective: To develop a conceptual prediction model framework containing standardized steps and describe
the corresponding open-source software developed to consistently implement the framework across computa-
tional environments and observational healthcare databases to enable model sharing and reproducibility.
Methods: Based on existing best practices we propose a 5 step standardized framework for: (1) transparently defin-
ing the problem; (2) selecting suitable datasets; (3) constructing variables from the observational data; (4) learning
the predictive model; and (5) validating the model performance. We implemented this framework as open-source
software utilizing the Observational Medical Outcomes Partnership Common Data Model to enable convenient
sharing of models and reproduction of model evaluation across multiple observational datasets. The software im-
plementation contains default covariates and classifiers but the framework enables customization and extension.
Results: As a proof-of-concept, demonstrating the transparency and ease of model dissemination using the soft-
ware, we developed prediction models for 21 different outcomes within a target population of people suffering
from depression across 4 observational databases. All 84 models are available in an accessible online repository
to be implemented by anyone with access to an observational database in the Common Data Model format.
Conclusions: The proof-of-concept study illustrates the framework’s ability to develop reproducible models that
can be readily shared and offers the potential to perform extensive external validation of models, and improve
their likelihood of clinical uptake. In future work the framework will be applied to perform an “all-by-all” predic-
tion analysis to assess the observational data prediction domain across numerous target populations, out-
comes and time, and risk settings.
Key words: Prediction model, prediction framework, prognostic model, observational data
INTRODUCTION
Observational healthcare data, such as administrative claims and elec-
tronic health records, are increasingly used for clinical characteriza-
tion of disease progression, quality improvement, and population-
level effect estimation for medical product safety surveillance and
comparative effectiveness. Advances in machine learning for large
dataset analysis have led to increased interest in applying patient-level
prediction on this type of data. Patient-level prediction offers the po-
tential for medical practice to move beyond average treatment effects
and to consider personalized risks as part of clinical decision-making.
Many published efforts in patient-level-prediction do not follow the
model development guidelines,1,2 fail to perform extensive external
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validation,3,4 or provide insufficient model details5 that limits the
ability of independent researchers to reproduce the models and per-
form external validation.1 This makes it hard to fairly evaluate the
predictive performance of the models and reduces the likelihood of
the model being used appropriately in clinical practice. To improve
standards, several papers have been written detailing guidelines for
best practices in developing and reporting prediction models. For ex-
ample, the prognostic research strategy consists of 4 papers stating a
variety of best practices aimed at general considerations,6 prognostic
factor discovery,7 model development,8 and making clinical impacts
by implementing the model to enable stratified medicine.9 The Trans-
parent Reporting of a multivariable prediction model for Individual
Prognosis Or Diagnosis statement provides clear recommendations
for reporting prediction model development and validation5 and
addresses some of the concerns related to transparency. However,
data structure heterogeneity and inconsistent terminologies still make
collaboration and model sharing difficult as different researchers are
often required to write new code to extract the data from their data-
bases and may define variables differently.
We propose to facilitate adherence to the best practices proposed
in prognostic research strategy by forming collaborations between
various data holders and researchers and developing a conceptual
framework that standardises the process of developing, evaluating,
and reporting predictive models. Such a strategy enables large-scale
exploration of prediction problems and improves transparency and
sharing of research within the prediction model community, but
requires standardization of the observational data to a shared data
model and terminology. Fortunately, there has already been a col-
laborative effort to standardise terminologies and develop a homog-
enous data structure for observational healthcare data via the
Observational Health Data Sciences and Informatics (OHDSI) col-
laboration. OHDSI is an open science collaborative with an interna-
tional network of researchers and data partners, who focus on
methodological research, open-source analytics development, and
clinical applications to advance the generation and dissemination of
reliable medical evidence from observational data.10 The OHDSI
community has adopted the Observational Medical Outcomes Part-
nership (OMOP) Common Data Model (CDM),11 an open commu-
nity standard for standardizing the structure and content of
observational data. Use of the OMOP CDM across participating
researchers enables studies to be consistently developed, executed
and replicated across collaborator sites. A recent investigation of
treatment pathways for three diseases12 highlights the power of uti-
lizing the OHDSI network, as collaborators efficiently replicated the
study across numerous diverse datasets from around the world.
In this paper, we propose a standardised framework for patient-
level prediction that utilizes the OMOP CDM and standardized vocab-
ularies, and describe the open-source software that we developed imple-
menting the framework’s pipeline. The framework is the first to
support existing best practice guidelines and will enable open dissemi-
nation of models that can be extensively validated across the network
of OHDSI collaborators. As a proof-of-concept we apply the frame-
work to 4 different databases for the clinical problem of predicting the
1-year risk of 21 different medical outcomes for a target population of
patients with pharmaceutically-treated depression.
Observational Healthcare Data and the OMOP CDM
In general, a prediction task can be defined as using a labeled data-
set, consisting of a set of prediction variables paired with a label, to
learn the function that maps as closely as possible the prediction var-
iables to the correct label. In contrast, in observational healthcare
data, patients yield a series of time-stamped clinical elements
(termed clinical concepts) across a variety of concept domains (such
as conditions, drugs, procedures, and measurements) based on their
encounters with the health system or other reporting of their health
information. A common strategy for transforming these data to the
labeled analytic data need for prediction is to create a population of
patients at risk of the health outcome being predicted (termed the
target population) and selecting a single time point for each patient
(target population index date) that provides the perspective for
extracting the prediction variables; only clinical elements prior to or
on the same day as the target population index date can be consid-
ered when extracting prediction variables. Finding which patients
experience the health outcome during some time-at-risk period rela-
tive to the target population index date then determines the labels.
To ensure that such a transformation process is portable across
multiple healthcare databases requires the use of a CDM. The
OMOP CDM improves semantic and syntactic interoperability by
standardizing both data structure and language.
METHODS
Standardized Prediction Framework
Our proposed conceptual has 5 steps:
0. Map the raw observational healthcare data into the OMOP CDM
1. Specify the prediction problem
• Define the target population, the patients to whom you wish to apply
to model. The target population is a set of patients who satisfy one
or more inclusion criteria for a duration of time. For example, a tar-
get population could be patients who start depression treatment ob-
served from the time of treatment initiation until treatment cessation.
• Define the outcome for which you wish to predict the risk. The
outcome is also a population defined as a set of patients who sat-
isfy one or more inclusion criteria for a duration of time. For ex-
ample, an outcome population could be patients who experience
stroke observed at the time of first diagnosis.
• Define the time-at-risk period; this is the time interval within
which you wish to predict the outcome occurring. For example,
patients with depression treatment may be at risk of stroke from
the day following treatment initiation through 1 year following
treatment initiation.
2. Select the dataset that will be used to develop the model
• Check that the target population is of sufficient size for model de-
velopment.
• Check that there a sufficient number of outcomes in the target
population during the time at risk.
3. Select from a set of standardized predictor variables (although we
strongly recommend selecting all standardized variables).
• Can pick different time periods to construct variables prior to
time-at-risk start date.
• Can pick from demographics, conditions, drugs, measurements,
procedures and observations concepts.
• Can group concepts based on a hierarchy in the vocabulary.
4. Select the machine learning models that will be trained, training
settings, and the hyper-parameter search strategy.
5. Generate and validate each model internally and externally.
Specifying the prediction problem
To standardize the prediction problem, we define the generic ques-
tion in the form: “Among <target population>, which patients will
develop <an outcome> during <a time-at-risk period>?” We define
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both target populations and outcomes as an index rule specifying
the index date (e.g., the occurrence of some diagnosis), possibly ac-
companied by a set of inclusion rules. Rules can reference one or
more clinical concepts, and because we adopt the OMOP CDM
these concepts arise from standardized vocabularies. We have opted
to define outcomes independently of the target population. This
way, it is possible to reuse outcome definitions for different predic-
tion problems as we determine the outcome not just for the target
population, but for all possible populations. For example, we may
create a definition of “stroke” to create predictive models both in a
population of diabetics as well a population of patients suffering
from depression. We recommend that both the definitions and the
code implementing a definition be available on an online repository,
for example, the OHDSI GitHub repository.
The final part of the prediction problem definition is to define
the time-at-risk, an interval relative to the target population index
date in which we wish to predict the occurrence of the outcome of
interest. We then label each patient in the target population as hav-
ing the outcome or not having the outcome in their time-at-risk. The
result is a labeled analytic dataset that is used by a classifier to learn
a predictive model. The prediction problem is illustrated in Figure 2.
Selecting the observational dataset
The next step is to pick the observational dataset mapped to the
OMOP CDM on which to learn a predictive model. Selection of a
dataset can be driven by, for example, the number of people in the tar-
get population and the number of people that experience the outcome.
Having too few people in the target population with the outcome is
known to limit the prediction model’s performance; therefore, we ad-
dress this in the framework by adding a minimum constraint on out-
come counts that we check prior to model development.
Selecting from standardized predictor variables
One key aspect of the standardized patient-level prediction framework
is its automated construction of predictor variables. The framework
contains a library of potential predictor variables. The predictor varia-
bles are well-defined and, by utilizing the OMOP CDM data structure,
their construction is readily replicated across datasets. The standard
predictor variables that are assessed relative to the index date include:
• Demographics: age, gender, index month
• All conditions/drugs/measurements/procedures/observations recorded
within n days prior to index (default n¼365)
• All conditions/drugs/measurements/procedures/observations recorded
anytime prior to index
• Hierarchal groupings of the conditions/drugs/measurements/pro-
cedures/observations
• All standard concept count variables
In addition, there is the flexibility to create custom predictor varia-
bles. The library of potential predictors will be extended consider-
ably in the future based on our ongoing research efforts in advanced
feature engineering.
The notion of “missing values” does not easily apply to longitudi-
nal observational data. Conditions or drugs may or may not be
Figure 1. Illustration of how the homogeneous structure of the OMOP common data model enables sharing of model development code.
Figure 2. Illustration of the prediction problem. Patients enter the target popula-
tion when they experience the index event (blue rectangle). For each patient,
prediction variables are constructed using data recorded prior to the index date,
and the presence of the outcome of interest is assessed during the time-at-risk.
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recorded, but it is not possible to determine whether a count of 0 indi-
cates the patient did not have the variable or whether it was missing.
Effectively, by default the framework imputes 0 for missing values
but there is also the opportunity to add custom covariates that per-
form imputation. Our framework would enable the evaluation of im-
putation methods at scale with respect to performance and
computational cost. This is an interesting subject for our future work.
Selecting the classifier and settings
We split the labeled data created during the prior steps into a test set
and train set. Within the package, the default split is 75% into the
train set and 25% in the test set, but this can be modified. We then
train a selection of suitable machine learning classifiers using the
training dataset through n-fold cross validation to select the optimal
hyper-parameters of the classifier. For each classifier, the framework
returns the hyper-parameter setting that obtains the best perfor-
mance (based on the objective function) as determined by cross-
validation on the train set. As a best practice, we propose executing
a wide array of machine learning algorithms for each prediction
problem, comparing their performances, and then selecting the algo-
rithm that is most suitable for the prediction problem.
Validating the predictive model
We internally validate the models on the test set and externally vali-
date by applying them to new data extracted from different datasets
(using the same extraction process). We use the area under the re-
ceiver operator characteristic curve (AUC) to measure discrimina-
tion, which calculates the probability that a randomly chosen
patient with the outcome will be assigned a higher risk of the out-
come by the model than a randomly chosen patient without the out-
come. We generate the receiver operator characteristic curve by
plotting the model’s sensitivity against 1-specificity. We also calcu-
late model calibration, indicating how well the predicted risks match
the observed true risk. The calibration is calculated by creating 10
bins based on predicted risk and for each bin calculating the average
predicted risk and fraction of patients with the outcome. These val-
ues are then plotted to develop a standard calibration plot. In addi-
tion, a linear model is fitted to the 10 values and the intercept/slope
is calculated to give a summary of the model calibration.
Implementation of the Standardized Prediction
Framework
The framework is implemented as a set of R packages, which are avail-
able as open source (https://github.com/ohdsi). The central package is
the PatientLevelPrediction which implements most steps of the frame-
work described above. The package contains default covariates and
classifiers, but users can readily add custom covariate construction
code or add new classifiers. The cohort definitions, the model details,
and model performance measures are all stored which enables full re-
producibility and external validation. See Supplementary material SA
for detailed information about the framework implementation.
RESULTS
The Prediction Problem
We test the framework for the problem: “Amongst patients with
pharmaceutically-treated depression, which patients will develop <an
outcome> during the 1-year time interval following the start of the de-
pression episode?.” The aim here was not to obtain the best possible
model for this problem but to demonstrate the use of the framework.
We developed prediction models for 21 outcomes listed in Table 2.
Target Population (Pharmaceutically-treated depression)
• Index rule defining the target population index dates:
• First condition record of major depressive disorder
• Target population end date: Same as target population index
date
• Inclusion criteria:
• Antidepressant recorded within 30 days before to 30 days af-
ter the target population index date
• No history of psychosis
• No history of dementia
• No history of mania
• 365 days prior observation
See Supplementary material SD for a complete list of definitions
used above.
Datasets Used to Develop the Model
We used the following datasets:
• Truven MarketScan Medicare Supplemental Beneficiaries
(MDCR)—a US insurance claims database containing 9 559 877
lives between the years January 1, 2000 and April 30, 2016,
• Truven MarketScan Medicaid (MDCD)—a US insurance claims
database containing 21 577 517 lives between the years January
1, 2006 and December 31, 2014,
• OptumInsight’s de-identified ClinformaticsTM Datamart
(Optum)—a US electronic healthcare database containing
73 969 539 lives between the years May 1, 2000 and March 31,
2016, and
• Truven MarketScan Commercial Claims and Encounters
(CCAE)—a US insurance claims database containing
131 533 722 lives between the years January 1, 2000 and April
30, 2016.
The use of Truven Health MarketScanV
R
and Optum databases
were reviewed by the New England Institutional Review Board and
were determined to be exempt from broad Institutional Review
Board approval.
Selected Standardized Predictor Variables
In this study we use the standardized variables described earlier, re-
moving variables occurring in less than 10 patients. As a result we
had approximately 10 000–17 000 variables, depending on the
dataset.
Machine Learning Model
For this proof-of-concept, we train an L1-regularized logistic regres-
sion using 3-fold cross validation auto hyper-parameter selection as
implemented in the R package Cyclops.15
Full details of the model development, specification and perfor-
mance can be found in the supplementary material SA. In addition
to the L1-regularized logistic regression we also trained gradient
boosting machine, random forest, and naı¨ve Bayes models.
Study Population
Table 1 presents the number of target population patients with each
outcome recorded during their time-at-risk period.
Table 2 presents characteristics of the patients for each dataset’s
target population. The target population obtained from the
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MDCD database appeared to have a shorter observation prior to
the target population index date, a mean of 973.4 days compared
to 1216.4–1262.4 for the other databases. MDCD also had a lower
percentage of males (26.3%) in the target population compared to
the other databases (ranging between 34% and 37%). MDCR con-
sists of an older target population than the other databases and
CCAE only contains people <65 years old. MDCR and MDCD
had target populations consisting of people who had more drug
and condition records in the prior 30 and 365 days than CCAE and
OPTUM.
Internal Validation
Table 3 presents the performance of the models developed for the
difference outcomes across the datasets. The discrimination per-
formance differs over the outcomes and databases. For example,
the framework led to highly discriminative models for the out-
comes such as ventricular arrhythmia and sudden cardiac death
and hypothyroidism across the 4 databases, with AUCs ranging
between 0.732–0.808 and 0.763–0.845, respectively. However,
for the outcomes diarrhea and tinnitus the discrimination was
consistently poor across the dataset, ranging between 0.636–
0.682 and 0.576–0.696, respectively. This suggests that observa-
tional databases could be utilized to develop clinically useful mod-
els that predict some outcomes, but certain types of outcomes
may need more advanced methods or alternative datasets. In some
cases there was inconsistency across databases, for example, pre-
dicting open-angle glaucoma in MDCD resulted in an AUC of
0.624, but the AUC for the same outcome in the other 3 data-
bases was >0.7.
The calibration plots for each model are available in Supplemen-
tary material SB and the reciever operating characteristic (ROC)
plots in Supplementary material SC. The intercept and slope of the
linear model fit to the average predicted risk against the observed
fraction with the outcome in bins of 10 based on risk percentile are
also presented in Table 3 as a summary of calibration. However, we
recommend inspecting the calibration plots as the intercept and
slope only present a limited perspective of calibration.
DISCUSSION
The proposed framework succeeds in developing transparent predic-
tive models that were developed in a consistent way across the data-
sets for predicting various outcomes within a target population of
therapeutically treated depressed patients. As a proof-of-concept we
shared results for lasso regression models (and 3 other classifiers) for
21 outcomes in patients with pharmaceutically treated depression.
However, we believe that model selection is an empirical process
and multiple model types should be assessed as a best practice. Our
framework is built for this purpose, and is very flexible to accommo-
date unlimited model types, custom covariates, etc. In general, com-
mon prediction models that are clinically used tend to have a AUC
ranging between 0.5 and 0.8,16–19 with many having a value <0.7,16
so the performance of our framework across the 21 outcomes is
comparable, although the external validation discrimination is likely
to be lower than the internal validation.
The implications of the proposed patient-level prediction frame-
work are: (1) a common framework will encourage collaboration
when developing patient-level prediction; (2) the standardizations
present the opportunity to develop and validate predictive models
using observational data at scale; and (3) insight in to the feasibility
of model development for specific diseases can be investigated.
The patient-level prediction framework and software directly or
indirectly address most of the best practices mentioned in the intro-
duction. One best practice suggests choosing prediction problems that
can make an impact, and this can be indirectly addressed as the
framework does now present the opportunity to efficiently perform a
large-scale exploration of various prediction problems (different tar-
get populations, outcomes, and times-at-risk) across numerous obser-
vational datasets. This enables identification of prediction problems
where sufficiently good performance can be achieved, thus making
for potentially impactful targets. A second consideration, collabora-
tion, and sharing of research, follows immediately as the purpose of
the proposed framework and software is to encourage collaboration.
The Transparent Reporting of a multivariable prediction model for
Individual Prognosis Or Diagnosis statement furthermore touches on
research transparency, and the framework provides open-source
Table 1. The Number of Outcomes Within the Target Population for the Various Outcomes Across the Datasets.
Outcome CCAE (N¼ 660 k) [%] OPTUM (N¼ 363 k) MDCR (N¼ 58 k) MDCD (N¼ 80 k)
Open-angle glaucoma 249 [0.04] 610 [0.17] 113 [0.19] 59 [0.07]
Gastrointestinal hemorrhage 1153 [0.17] 823 [0.23] 534 [0.92] 238 [0.30]
Acute myocardial infarction 1000 [0.15] 814 [0.22] 578 [1.00] 211 [0.26]
Stroke 1351 [0.20] 1183 [0.33] 874 [1.51] 356 [0.45]
Suicide and suicidal ideation 17 992 [2.73] 9530 [2.63] 575 [0.99] 4609 [5.76]
Insomnia 34 838 [5.28] 22 635 [6.24] 2941 [5.07] 5358 [6.70]
Diarrhea 30 632 [4.64] 20 169 [5.56] 3667 [6.32] 5431 [6.79]
Nausea 38 686 [5.86] 25 312 [6.97] 3876 [6.68] 8257 [10.32]
Hypothyroidism 15 422 [2.34] 10 123 [2.79] 2079 [3.58] 1822 [2.28]
Constipation 22 636 [3.43] 16 237 [4.47] 3835 [6.61] 5247 [6.56]
Seizure 3594 [0.54] 2377 [0.65] 487 [0.84] 1165 [1.46]
Delirium 2440 [0.37] 1861 [0.51] 797 [1.37] 569 [0.71]
Alopecia 5087 [0.77] 3234 [0.89] 329 [0.57] 451 [0.56]
Tinnitus 6381 [0.97] 4407 [1.21] 938 [1.62] 576 [0.72]
Vertigo 6486 [0.98] 4170 [1.15] 1034 [1.78] 657 [0.82]
Hyponatremia 4539 [0.69] 4861 [1.34] 1789 [3.08] 1463 [1.83]
Decreased libido 2832 [0.43] 1755 [0.48] 91 [0.16] 171 [0.21]
Fracture 7532 [1.14] 6273 [1.73] 2606 [4.49] 1371 [1.71]
Hypotension 8525 [1.29] 8185 [2.25] 2888 [4.98] 2603 [3.25]
Acute liver injury 387 [0.06] 306 [0.08] 44 [0.08] 114 [0.14]
Ventricular arrhythmia and sudden cardiac death 806 [0.12] 730 [0.20] 355 [0.61] 315 [0.39]
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software that is fully transparent and promotes model reproducibility.
Researchers can even share their models by adding them via the
OHDSI GitHub repository. Our framework also explicitly covers the
consideration of terminology and methodology standardization, as
the framework proposes a standard process that can be followed to
develop prediction models and uses existing standard terminologies.
Table 2. Target Population Characteristics Across the Datasets
Variable CCAE OPTUM MDCR MDCD
Mean (sd) prior obs in days 1262.4 (944.3) 1234.6 (886.3) 1216.4 (881.6) 973.4 (593.3)
Mean (sd) No. condition records 365 days 12.7 (10.2) 16.8 (13.3) 20.1 (14.5) 22.3 (16.7)
Mean (sd) No. drug ingredients 365 days 9.4 (7.2) 9.0 (6.8) 12.5 (7.7) 13.8 (9.8)
Mean No. visits in prior 365 days 24.4 (21.1) 26.3 (24.7) 31.6 (24.7) 54.7 (77.4)
(%) Gender¼Male 37.0 36.6 34.0 26.3
(%) Age group: 0–4 0.0 0.0 0.0 0.0
(%) Age group: 5–9 0.1 0.1 0.0 1.2
(%) Age group: 10–14 2.0 1.8 0.0 8.7
(%) Age group: 15–19 9.3 7.8 0.0 16.3
(%) Age group: 20–24 7.0 5.4 0.0 5.2
(%) Age group: 25–29 4.7 4.9 0.0 7.2
(%) Age group: 30–34 7.6 7.5 0.0 7.7
(%) Age group: 35–39 9.8 9.4 0.0 7.9
(%) Age group: 40–44 11.5 10.6 0.1 8.5
(%) Age group: 45–49 12.8 11.3 0.6 10.1
(%) Age group: 50–54 13.8 11.0 1.6 10.6
(%) Age group: 55–59 12.7 9.5 3.2 8.2
(%) Age group: 60–64 8.8 6.8 4.0 5.0
(%) Age group: 65–69 0.0 4.7 30.4 1.7
(%) Age group: 70–74 0.0 3.5 23.2 0.8
(%) Age group: 75–79 0.0 2.5 16.8 0.4
(%) Age group: 80–84 0.0 2.3 11.7 0.3
(%) Age group: 85–89 0.0 0.9 6.1 0.28
(%) Age group: 90–94 0.0 0.0 1.9 0.0
(%) Age group: 95–99 0.0 0.0 0.4 0.0
Table 3. Discrimination Performance of the Models for Each Outcome Across the Datasets
Outcome Discrimination (AUC) Calibration
CCAE OPTUM MDCR MDCD CCAE OPTUM MDCR MDCD
Intercept Slope Intercept Slope Intercept Slope Intercept Slope
Open-angle glaucoma 0.817 0.822 0.710 0.624 0.000 1.051 0.000 0.990 0.001 1.495 0.000 1.399
Gastrointestinal hemorrhage 0.824 0.797 0.677 0.754 0.000 0.868 0.000 1.009 0.001 0.952 0.000 0.633
Acute myocardial infarction 0.863 0.808 0.697 0.787 0.000 1.048 0.000 0.916 0.003 1.404 0.000 1.263
Stroke 0.797 0.813 0.661 0.803 0.000 0.783 0.000 0.750 0.001 0.833 0.000 1.082
Suicide and suicidal ideation 0.796 0.805 0.690 0.710 0.002 1.711 0.002 1.720 0.006 1.387 0.002 1.773
Insomnia 0.683 0.667 0.672 0.636 0.023 1.314 0.010 1.305 0.029 1.379 0.025 1.109
Diarrhea 0.682 0.674 0.636 0.680 0.012 1.095 0.005 1.116 0.023 1.083 0.009 1.253
Nausea 0.701 0.675 0.651 0.668 0.021 1.111 0.015 1.099 0.034 0.999 0.036 1.152
Hypothyroidism 0.842 0.792 0.839 0.763 0.002 1.343 0.000 1.051 0.002 1.557 0.001 1.261
Constipation 0.704 0.705 0.651 0.645 0.010 1.132 0.005 1.238 0.027 1.080 0.010 1.268
Seizure 0.753 0.757 0.649 0.696 0.000 1.216 0.000 0.984 0.001 1.212 0.001 1.107
Delirium 0.782 0.781 0.702 0.664 0.000 0.998 0.001 0.733 0.001 0.855 0.002 0.830
Alopecia 0.692 0.672 0.684 0.625 0.002 1.293 0.001 1.323 0.001 2.568 0.001 1.244
Tinnitus 0.696 0.672 0.576 0.638 0.003 1.152 0.001 1.368 0.006 1.372 0.002 1.292
Vertigo 0.714 0.705 0.619 0.679 0.002 1.214 0.000 1.229 0.006 1.251 0.002 1.242
Hyponatremia 0.808 0.809 0.690 0.795 0.001 1.073 0.001 1.141 0.002 1.298 0.002 1.137
Decreased libido 0.710 0.738 0.662 0.627 0.002 1.179 0.000 1.684 0.002 5.095 0.001 0.893
Fracture 0.674 0.734 0.679 0.657 0.001 1.037 0.001 1.119 0.007 1.019 0.002 1.553
Hypotension 0.761 0.793 0.709 0.749 0.003 1.112 0.002 1.116 0.011 1.195 0.004 1.191
Acute liver injury 0.703 0.743 0.516 0.534 0.000 0.998 0.000 0.919 0.003 5.698 0.001 0.036
Ventricular arrhythmia and
sudden cardiac death
0.776 0.806 0.732 0.808 0.000 0.857 0.000 1.034 0.000 0.806 0.001 1.105
An AUC of 0.5 means the model discriminated as well as random guessing and an AUC of 1 means perfect discrimination. For calibration, and intercept of 0
and slope of 1 means perfect calibration.
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The main limitation of the framework is that it requires research-
ers to map their data into the OMOP CDM. Although there is mini-
mum information lost,20 the mapping requires time and effort.
However, the OHDSI community is already large and rapidly
expanding, and the clear advantages of a common data model such
as proposed in this research may prompt more researchers towards
using a consistent data structure. The power of collaboration lead-
ing towards improved predictive models has been highlighted in re-
cent literature. A pre-requisite to do this at large-scale is a uniform
process to predictive model development, which we now support
through the presented framework.
Our framework proposes a standardised process for model devel-
opment and standard output, as these are important for both repro-
ducibility and model comparisons. However, we understand that
there is ongoing research in the field, so the framework has the flexi-
bility to incorporate new modeling methods or metrics. It is important
for the community to be consistent in the way model performances
are presented, and this framework aims to ensure consistency, but the
framework’s standard output will evolve with the field.
CONCLUSION
In this paper we propose a standardized framework and introduce
open-source software that can work across computer environments
to generate patient-level prediction models from observational
healthcare data in a manner that is transparent and completely re-
producible. As a proof-of-concept, we applied the framework to the
problem of predicting 21 different outcomes for the target popula-
tion of pharmaceutically-treated depression across 4 different data-
bases. The framework succeeds in efficiently developing and
evaluating 21 different models in 4 different databases, and stan-
dardizing those models so they can be directly applied to any obser-
vational data in the CDM structure.
Although several papers propose best practices for predictive
model development,5–9 this work is the first to propose an implemen-
tation that can enable model transparency and reproducibility. The
proposed framework addresses and implements key best practice con-
siderations and encourages researchers to collaborate and share mod-
els. It facilitates transportability assessment at scale which will
increase the likelihood of model implementation in clinical practice.
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